ATB Therapeutics develops first‑in‑class biologics that integrate novel enzymatic and cytotoxic functionalities into targeted antibodies. Its proprietary ATBioFarm platform enables scalable, single‑step production of antibodies that combine multiple targeting and killing domains. The company is advancing a pipeline of ‘‘weaponized’’ antibodies intended to improve efficacy and safety compared with traditional conjugates. Proceeds from the recent financing are intended to accelerate clinical development of oncology and immunology candidates and to expand the ATBioFarm technology. ATB will extend research and development operations to Ghent and continue work in Marche‑en‑Famenne, where it is setting up a pilot manufacturing facility. Leadership was strengthened as industry veteran Mark Throsby joined as Executive Chair and investor partners joined the board.

Total raised

$63M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2024